Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory Bowel Disease in Children.

Mihaela Ringheanu1, James Markowitz

  • 1Division of Pediatric Gastroenterology and Nutrition, North Shore- Long Island Jewish Health System, 300 Community Drive, Manhasset, NY 11030, USA. jamesm@nshs.edu

Current Treatment Options in Gastroenterology
|May 11, 2002
PubMed
Summary

Treating Crohn's disease and ulcerative colitis in children involves symptom reduction, nutritional support, and growth optimization. Effective management combines nutritional and pharmacologic therapies to induce and maintain remission, with emerging treatments offering future hope.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline terminal ileal CT and MRI measurements are associated with imaging outcomes in pediatric Crohn's disease: a cohort study.

Pediatric radiology·2025
Same author

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.

Alimentary pharmacology & therapeutics·2025
Same author

P072 Non-invasive Vagal Nerve Stimulation to Treat Crohn Disease and Ulcerative Colitis in Children and Young Adults: A Proof-of-Concept Clinical Trial.

The American journal of gastroenterology·2023
Same author

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study.

Crohn's & colitis 360·2023
Same author

Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.

Journal of Crohn's & colitis·2022
Same author

Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression.

American journal of human genetics·2021

Area of Science:

  • Pediatric Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Therapeutics

Background:

  • Crohn's disease (CD) and ulcerative colitis (UC) are chronic, incurable inflammatory bowel diseases (IBD) causing significant morbidity in children.
  • Current treatment goals include symptom control, nutritional optimization, normal growth, complication prevention, and minimizing psychologic impact.

Purpose of the Study:

  • To outline optimal treatment strategies for pediatric CD and UC, focusing on inducing and maintaining clinical remission.
  • To discuss the roles of nutritional therapy, pharmacologic agents, and surgery in managing these conditions in children.

Main Methods:

  • Review of current therapeutic approaches for pediatric CD and UC.
  • Analysis of pharmacologic agents including corticosteroids, infliximab, 6-mercaptopurine (6-MP), azathioprine (AZA), and 5-aminosalicylates (5-ASA).

Related Experiment Videos

  • Evaluation of nutritional interventions like enteral nutrition and the role of surgery.

    • Main Results:

    • Combination therapy (nutritional and pharmacologic) is optimal for most pediatric CD cases.
    • Potent immunomodulatory therapy (corticosteroids, infliximab) combined with 6-MP/AZA is effective for moderate-to-severe CD remission.
    • Nutritional therapy can induce remission in CD, but relapse is common, necessitating pharmacologic support. Mild UC responds to 5-ASA; severe UC requires potent immunomodulators to avoid colectomy.

    Conclusions:

    • Optimizing pediatric IBD treatment requires a multifaceted approach combining nutrition, pharmacotherapy, and potentially surgery.
    • Monitoring 6-MP/AZA metabolite levels aids in optimizing therapy and minimizing toxicity.
    • Emerging biologic and probiotic therapies hold promise for improved future treatments for pediatric IBD.